HBVM阳性肺结核病人用利福喷丁或利福平治疗肝功能损害观察

目的 观察利福喷丁、利福平对ＨＢＶＭ阳性肺结核病人肝功能的影响。方法 对ＨＢＶＭ阳性和阴性肺结核病人分别用利福喷丁和利福平治疗，观察治疗前后肝功能损害情况。结果 利福平组较利福喷丁组出现肝损害多（Ｐ〈０．０１）；ＨＢＶＭ阳性较阴性病人易出现肝损害（Ｐ〈０．０１）；利福平组ＨＢＶＭ阳性较阴性病人出现肝损害多（Ｐ〈０．０１）；利福喷丁组ＨＢＶＭ阳性和阴性肝损害发生率无显著差异（Ｐ〉０．０５）。结论 抗     

小儿乙型肝炎干扰素治疗的有关问题

我国成人中慢性ＨＢＶ携带者和成人期肝癌大部分源于儿童期ＨＢＶ感染。小儿肝癌中，ＨＢＶ感染导致者高达３４％～９５％。小儿肝癌可发生在儿童期ＨＢｅＡｇ转换为抗－ＨＢｅ无肝硬化的年轻人。我们对７４３例经过肝脏组织病理诊断的小儿乙型肝炎的研究结果显示，小儿乙型肝炎绝大多数缺乏典型的临床症状。其ＡＬＴ升高与肝脏病理损害也不完全一致。４１％小儿乙型肝炎（３０５／７４３例）因ＡＬＴ正常误诊为“健康携带者”，肝脏有活动性病变而得不到及时的治疗。我们对９４例经肝脏组织学检查的乙型肝炎患儿分析显示，６６％为查体发现…     

抗结核组合药对HBVM阳性肺结核病人肝功能影响的观察

目的 观察抗结核组合药对ＨＢＶＭ阳性肺结核病人肝功能的影响。方法 比较ＨＢＶＭ阳性和阴性肺结核病人组合药治疗前后肝功能损害情况。结果 ＨＢＶＭ阳性病人肝损率比阴性者明显增高（Ｐ〈０．０１）;其中“模式Ⅰ”与“模式Ⅱ”病人肝损率差异不显著（Ｐ〉０．０５）,而“模式Ⅰ＋Ⅱ”病人肝损率比“模式Ⅲ”高（Ｐ〈０．０５）。结论 组合药致肝功能损害,ＨＢＶＭ阳性病人比阴性多见,尤以“模式Ⅰ、Ⅱ”病人更易发生,可能与用药前肝脏病理损害严重程度有关。应慎用组合药并积极采取综合措施防范。     

慢性乙型肝炎患者血清HBVDNA负荷与其肝组织炎症活动度的相关性研究

探讨慢性乙型肝炎患者血清ＨＢＶＤＮＡ水平与其肝组织炎症活动度的相关性。随机选择８２例慢性乙型肝炎患者，检测其血清ＨＢＶＤＮＡ和ＡＬＴ水平，肝穿刺活检，光镜多视野观察其肝组织炎症活动度。随着慢性乙型肝炎患者血清ＨＢＶＤＮＡ水平升高，其血清ＡＬＴ和肝组织炎症活动度明显升高（Ｐ＜０．０５）。慢性乙型肝炎患者ＨＢＶＤＮＡ负荷与其肝组织炎症活动度有相关性。     

慢性乙型肝炎血清HBVDNA临床诊断与病理分度的关系

为探讨慢性乙型肝炎时血清ＨＢＶＤＮＡ与病理分度，临床诊断便分度的关系，对１４０例慢性乙型肝炎患者进行ＨＢＶＤＮＡ检测，肝活检，行临床诊断与病理分度对照，ＨＢＶＤＮＡ阴，阳组间比较。结果显示临床诊断与病理分度符合率，慢轻肝７５．８％，慢中肝４３．２８％，慢重肝不符合，ＨＢＶＤＮＡ阳性组病例程度明显加重，差异显著。随炎症活动度增加，ＡＬＴ值升高愈明显，结论提示慢性中重度患者应行病理检查，ＡＬＴ仍然观察     

a1b干扰素治疗慢性乙型肝炎

资料与方祛：１．对象：ｓｌ例慢性乙型肝炎患者,其中１７例经肝穿证实。年龄１４－４８岁。男性６４例,女性１７例。血清ＨＢＶＤＮＡ均阳性（ＰＣＲ法）,ＡＬＴ均升高。６７例ＨＢｅＡｇ阳性,１４例抗一ＨＢｅ阳性。２．治疗方法：用以ｆｏ－１＊Ｎ（深圳科兴生物制品有限公司）,每次５－６ＭＵ,皮下或肌肉注射,每日１次,２周后每周３次。分为３、６和９月疗程组。另３０例慢性乙型肝炎患者为对照组。３．观察方法：治疗组每半月复查ＡＬＴ,每月检查ＨＢＶ标志物、ＨＢＶＤＮＡ。治前以ＲＩＡ法检测血清铁蛋白,肝穿病理检查,肝…     

晚期血吸虫病患者乙型肝炎病毒DNA的检测及其意义

３１例晚期血吸虫病患者血清及肝组织乙型肝炎病毒ＤＮＡ（ＨＢＶ－ＤＮＡ）阳性率分别为９．７％及１９．４％低于血清及肝组织乙型肝炎病毒表面抗原（ＨＢｓＡｇ）检出率（分别为２９％及４８．４％），ＨＢＶ－ＤＮＡ阳性者病死率高（６６．６％），且死亡与肝病直接相关（肝衰竭及原发性肝癌）。ＨＢＶ－ＤＮＡ阴性患者病死率较低（１２％），其死亡与肝病无直接关系。结果提示，检测晚期血吸虫病患者ＨＢＶ－ＤＮＡ有重要意义。抗乙型肝炎病毒治疗对改善存在ＨＢＶ复制的晚期血吸虫病患者预后可能有重要作用，在血吸虫病疫区普及乙肝疫苗接种将对血吸虫病防治工作产生重大效益。     

强化抗痨治疗对乙型肝炎病毒感染患者肝功能的影响

随着化疗的不断进展，短程化疗已成为控制结核病的中心环节［１］，目前国内外倡导肺结核强化治疗方案，链霉素（ＳＭ）、异烟肼（ＩＮＨ）、利福平（ＲＦＰ）、吡嗪酰胺（ＰＺＡ）、四联中的Ｈ、Ｒ、Ｚ，对肝功能均有不同程度的损害。为探讨强化治疗方案对无症状乙型肝炎病毒携带者的肝功能影响，将我院１６０例肺结核患者强化治疗前后的肝功能及乙型肝炎病毒标志物（ＨＢＶ－Ｍ）检测情况报告如下。１临床资料１．１一般资料１６０例全部为初治浸润型肺结核住院患者，男性１０２例，女性５８例，年龄１７～６５岁，平均３７岁。５１例痰涂…     

慢性乙型肝炎中医辩证与病理,病毒指标的关系：附117例分析

对１１７例经肝活检证实的慢性乙型肝炎的中医辩证、病理、病毒复制指标进行综合分析。结果ＨＢｅＡｇ阳性者和ＨＢｓＡｇ、ＨＢｅＡｇ、抗－ＨＢｃ－ＩｇＭ三项同时阳性者其百分比虚证组均高于实证组，说明虚证患者ＨＢＶ复制活跃。本文提示，对临床辩证为虚证者，治疗时应注意调整，抑病毒复制。     

肺结核合并HBV感染患者血清HBV－DNA的检测及其意义

采用分子斑点杂交和酶连免疫吸附试验（ＥＬＩＳＡ）方法检测２６８例肺结核患者血清乙型肝炎病毒ＤＮＡ（ＨＢＶ－ＤＮＡ）及其它乙肝病毒标志物（ＨＢＶ－Ｍ），观察肺结核患者抗结核化疗中肝功能变化与血清ＨＢＶ－ＤＮＡ的关系。结果，２６８例肺结核患者血清ＨＢＶ－Ｍ阳性率为１９．０％，ＨＢＶ－ＤＮＡ阳性２０例（７．５％）；化疗中，肺结核合并ＨＢＶ－ＤＮＡ阳性组、肺结核合并ＨＢＶ－ＤＮＡ阴性其它ＨＢＶ－Ｍ阳性组、单纯肺结核组，肝功能受损率分别为９５％、１０％及５．１％。肺结核合并ＨＢＶ感染组、单纯ＨＢＶ－Ｍ携带者组、单纯肺结核组，肝功能受损率分别为４９％、１０％及５．１％。肺结核合并ＨＢＶ－ＤＮＡ阳性组死亡４例（１５％），且死亡与肝病直接相关（肝衰竭），３．５年后发生肝硬化２例。结果提示，检测肺结核患者血清ＨＢＶ－ＤＮＡ有重要意义。抗乙型肝炎病毒治疗对改善存在ＨＢＶ复制的肺结核患者的预后可能有重要作用，化疗前常规检查并有ＨＢＶ感染的肺结核患者血清ＨＢＶ－ＤＮＡ，可指导用药。     

HBVM阳性肺结核病人用利福喷丁或利福平治疗肝功能损害观察

目的 观察利福喷丁?利福平对HBVM 阳性肺结核病人肝功能的影响?方法 对HBVM 阳性和阴性肺结核病人分别用利福喷丁和利福平治疗,观察治疗前后肝功能损害情况?结果 利福平组较利福喷丁组出现肝损害多( P< 0-01) ;HBVM 阳性较阴性病人易出现肝损害( P< 0-01) ;利福平组HBVM 阳性较阴性病人出现肝损害多( P< 0-01) ;利福喷丁组HBVM 阳性和阴性肝损害发生率无显著差异( P> 0-05) ?结论 抗结核治疗时HBVM 阳性比阴性病人更易发生肝损害,与其用药前即存在肝病理损害有关,治疗肺结核用利福喷丁比利福平疗效好且安全?     

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

CONTEXT: American Thoracic Society guidelines recommend a 9-month course of therapy with isoniazid for treatment of persons with latent tuberculosis infection who are at high risk for reactivation of disease. Major liver injury has been reported with the alternative regimen, a 2-month course of pyrazinamide and rifampin. OBJECTIVE: To evaluate the rate of completion and incidence of hepatotoxicity of a short regimen of pyrazinamide and rifampin for latent tuberculosis as compared with standard isoniazid therapy before and after instituting an intensive monitoring program. Design, setting, and participants: Prospective cohort study of 224 patients in a community setting between 1999 and 2001. INTERVENTIONS: Daily pyrazinamide and rifampin for 2 months or daily isoniazid for 6 months. MAIN OUTCOME MEASURES: Treatment completion, hepatotoxicity (fourfold increase of alanine transaminase [ALT]), severe hepatotoxicity (40-fold increase in ALT). RESULTS: Treatment was completed by 71% (78 of 110 patients) in the pyrazinamide/rifampin group and by 59% (67 of 114 patients) in the isoniazid group (p = 0.07). Hepatotoxicity (ALT > 160 U/L) was documented in 13% (14 of 110 patients) in the pyrazinamide/rifampin group and in 4% (5 of 114 patients) in the isoniazid group (p = 0.03). Severe hepatotoxicity (ALT > 1,600 U/L) occurred in 2 of 43 patients (5%) receiving pyrazinamide/rifampin prior to instituting intensive monitoring. Once more intensive monitoring of liver enzymes was implemented, severe hepatotoxicity occurred in none of 67 patients. CONCLUSION: The risk of hepatitis in patients receiving pyrazinamide/rifampin for prevention of latent tuberculosis is increased threefold as compared to patients receiving isoniazid. When patients were monitored more intensively, severe hepatotoxicity did not develop, but the difference did not reach statistical significance (p = 0.15).     

HBVM阳性肺结核患者HBVDNA检测的临床意义

目的探讨HBVDNA(乙型肝炎病毒DNA)、HBVM(乙型肝炎病毒标志物)阳性肺结核患者抗结核治疗时对肝损害的影响。方法肺结核患者HBVM阳性且HBVDNA阳性为观察组A,HB-VM阳性、HBVDNA阴性者为观察组B,HBVM阴性为对照组C,观察各组抗结核药物肝损害发生率、停药率及A组HBVDNA水平与肝损害发生率、停药率有无相关。结果各组肝损害发生率两两比较均有显著性差异(P<0.01);A组停药率与其他两组均有显著性差异(P<0.01),B组与C组无显著性差异(P>0.05);A组HBVDNA水平与肝损害发生率、停药率无相关(P>0.05)。结论HBVM阳性尤其HBVDNA阳性肺结核化疗应重视,HBVDNA阴性者可短程化疗,HBVDNA阳性者都应慎行短程化疗。     

短程化疗中乙肝病毒标志物阳性对肝功能影响及处理

目的 探讨抗结核治疗中乙肝病毒感染对肝功能的影响及其对策。方法 回顾性分析1746例肺结核病人及其中160例药物性肝损害的相关临床资料。结果176例乙型肝炎病毒标志物(HBVM)阳性结核病人中有68例(38.6%)出现肝损害,HBVM阴性患者1490例中出现肝损害70例(4.7%),另有80例未测HBVM者中22例(27.5%)出现肝损害。HBVM阳性与阴性的肝损害发生率差异极显著(P<0.01)。在治疗过程中出现肝损时间多为15～90d。结论 短程化疗中乙肝病毒感染对肝功能有一定的影响,在抗结核治疗前检查HBVM及肝功能十分必要,对HBVM阳性者宜选择对肝脏损害较轻的药物,同时给予适当的护肝治疗,并密切监测肝功能的变化。     

酒精性肝病合并肝炎病毒感染的临床特点分析

目的 探讨酒精性肝病合并肝炎病毒感染的临床特点,评价酒精性肝病与肝炎病毒感染的关系.方法 选择我院2004年1月至2011年5月收治经确诊的271例酒精性肝病患者,对其临床资料及实验室结果进行回顾性分析.结果 271例酒精性肝病中118例(43.5％)肝炎病毒标志物阳性,其中乙型肝炎病毒标志物阳性的101例(37.3％),丙型肝炎病毒标志物阳性的2例(0.7％),戊型肝炎病毒标志物阳性的14例(5.2％),甲型肝炎病毒标志物阳性的1例(0.3％),无肝炎病毒感染的153例(56.5％).肝炎病毒感染阳性组上消化道出血、肝性脑病百分率比较差异有统计学意义(P＜0.05).两组血清肝功能均有不同程度的异常,且阳性组ALT、AST、TBil、GGT明显高于阴性组,差异有统计学意义(P＜0.05).结论 酒精与肝炎病毒对肝脏损伤有协同作用,酒精性肝病合并肝炎病毒感染加重肝脏的损伤.     

乙肝病毒感染对慢性乙肝肝硬化患者胃黏膜病变的影响

目的探讨乙肝病毒(HBV)感染对慢性乙肝、肝硬化患者胃黏膜病变的影响及其发病机制。方法2003-06～2004-02对河北医科大学第三医院感染科60例慢性乙肝、肝硬化患者同时行肝穿、胃镜、肝功能、血清肝炎病毒标志物检查,采用SP法检测肝及胃黏膜组织中HBsAg、HBcAg。结果(1)肝组织病理损害程度与胃黏膜病变程度成正比(r=0.483,P<0.01)。(2)56例中26例胃黏膜组织中可检测到HBsAg和(或)HBcAg,其病变以中重度为主。34例HBVM阴性患者中,病变以轻中度为主(P<0.01)。(3)肝组织与胃黏膜组织中HBsAg同时阳性17例;HBcAg同时阳性6例(P>0.05)。(4)血清及胃黏膜组织中HBsAg和(或)HBcAg同时阳性26例;HBVDNA同时阳性22例(P>0.05)。结论进一步证实了HBV可侵犯胃黏膜组织,并在其中复制,是导致慢性乙肝患者胃黏膜病变的重要因素。胃黏膜病变程度与胃黏膜组织HBV感染、肝组织病变程度密切相关;与血清及肝组织中HBV分布无关。     

Serum levels of macrophage migration inhibitory factor, Interleukin-17 and Interleukin-10 in patients with HBV-related liver disease

Objective To study the potential role of macrophage migration inhibitory factor(MIF),Interleukin-17(IL-17) and Interleukin-10(IL-10) in the development of HBV-related liver disease.Methods 48 patients with chronic hepatitis B(HBeAg negative and positive,24 cases;21cases of HBV-DNA negative and 27 cases of HBV-DNA positive),81 cases of hepatitis B patients with decompensated cirrhosis and 48 cases of primary liver cancer patients were collected as the experimental group,26 healthy people were as control group.Serum MIF,IL-17 and IL-10 were measured.Results MIF and IL-17 significantly increased,IL-10 significantly decreased in experimental group,compared with the control group(P<0.05),there was significant difference.In addition,there was no significant difference(P>0.05) between positive and negative of chronic hepatitis B.MIF,IL-17 and ALT levels were positively correlated(r=0.693,P<0.01;r=0.897,P<0.001),IL-10 and ALT was negatively correlated(r =-0.285,P=0.037).Conclusion These results indicated that MIF,IL-17 and IL-10 may participate in the pathological process of HBV-related liver disease,serum levels of MIF,IL-17 and IL-10 appear to reflect the severity of tissue injury in HBV-related liver disease.     

The impact of antituberculosis drugs upon liver function in patients with positive HBVM

Through the liver function analysis of 100 tuberculosis cases in the course of antituberculosis chemotherapy the authors found that the abnormal liver function rate turned to be 50% in the positive HBVM Group but only 2.4% in the negative, HBVM Group. There is a significant statistical difference between the two groups of cases (P less than 0.01). For this reason, the authors suggested the HBVM should be determined one by one before taking the antituberculosis chemotherapy in the area with high incidence of B-type hepatitis, the data indicated clearly that, the abnormal phenomena of liver function after the antituberculosis treatment for those patients, mainly caused by the drugs.     

抗结核药物相关性肝功能衰竭34例临床特征

目的分析抗结核药物诱发肝功能衰竭的临床特征及相关影响因素。方法回顾性分析34例抗结核药物治疗期间出现肝功能衰竭的病例资料,按≤35岁、36～55岁及>56岁3个年龄段进行临床特征及相关影响因素分析。采用χ~2检验进行统计分析。结果 34例抗结核药物性肝功能衰竭中男15例,女19例,年龄14～68岁,平均(38.2±10.5)岁;病死率为67.6%(23/34),而超急性肝功能衰竭(2例)和急性肝功能衰竭(8例)中女性7例,病死8例;≥56岁者11例全部为亚急性肝功能衰竭,死亡9例,与≤55岁患者比较,差异有统计学意义(P<0.01)。所有病例初始治疗为异烟肼、利福平、吡嗪酰胺联用,治疗至诊断为药物性肝功能衰竭(DILF)的时间为5～56 d(平均23 d)。34例中HBsAg阳性8例,3例HBsAg/抗-HBe阳性患者应用激素后1例HBeAg转为阳性,2例HBV DNA由低于检测下限出现高于检测下限;HBV血清标志物阳性者死亡率(6/8,75%)与阴性者死亡率(17/26,65.4%)比较,差异有统计学意义(P<0.05)。结论抗结核药物诱发的超急性肝功能衰竭和急性肝功能衰竭可能与遗传多态性及机体较强的免疫状态相关;亚急性肝功能衰竭则可能与老年人药物在肝脏代谢能力的改变相关;激素有增加HBV复制的可能性,与肝功能衰竭的预后相关。     

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy

STUDY OBJECTIVES: To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide. DESIGN: Retrospective case-control study. SETTING: Tertiary university medical center. PATIENTS: One hundred ten inactive HBsAg carriers with newly diagnosed active tuberculosis who had been treated with isoniazid, rifampin, ethambutol, and/or pyrazinamide were included in the study population. Inactive HBsAg carriers were defined as follows: (1) positive for HbsAg; (2) negative for hepatitis B e antigen (HBeAg), positive for antibody to HBeAg; (3) < 10(5) copies per mL of serum hepatitis B virus DNA; and (4) normal pretreatment aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels. Ninety-seven HBsAg-negative patients who received standard antituberculosis medication were selected as control subjects. RESULTS: The baseline characteristics of the 110 inactive HBsAg carriers were similar to those of the 97 noncarriers. A total of 85% of persons in both groups had received an initial treatment regimen that included pyrazinamide. Thirty-eight inactive HBsAg carriers (35%) and 19 control subjects (20%) exhibited elevated liver enzyme levels during antituberculosis treatment (p = 0.016). Drug-induced hepatotoxicity, which was defined as a liver transaminase level of >/= 120 IU/L, occurred more frequently in HBsAg carriers (9 of 110 carriers; 8%) than in control subjects (4 of 97 control subjects; 4%), although this was not a statistically significant discrepancy (p = 0.230). More importantly, HBsAg carriers (n = 9; 8%) who received antituberculosis therapy evidenced a higher proportion of moderate-to-severe drug-induced hepatotoxicity when compared with the control subjects (n = 2; 2%; p = 0.05). Isoniazid and rifampin were reintroduced as therapy after AST/ALT levels returned to baseline values in 10 patients (6 HBsAg carriers and 4 control subjects) among the 13 patients exhibiting drug-induced hepatotoxicity, and these retrials proved to be successful in 7 patients (5 HBsAg carriers and 2 control subjects). CONCLUSIONS: Tuberculosis treatment in HBsAg-positive and HBeAg-negative inactive carriers could be pursued in the usual manner, using standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide, with the condition that monthly liver function tests are performed.